Impurities test for Trimethoprim (EP-8.0 method) - For Impurities-H & I

Applications |  | Thermo Fisher ScientificInstrumentation
HPLC
Industries
Pharma & Biopharma
Manufacturer
Thermo Fisher Scientific

Significance of the Topic


Assessing impurities in active pharmaceutical ingredients is critical for ensuring drug safety, efficacy, and regulatory compliance. The European Pharmacopoeia method for quantifying Trimethoprim impurities H and I provides a standardized protocol to monitor trace-level contaminants that could impact product quality.

Study Objectives and Overview


The main goal of the study was to validate the European Pharmacopoeia (EP) 8.0 procedure for determining impurities H and I in Trimethoprim. The overview covers sample preparation, chromatographic conditions, system suitability assessment, and result interpretation under EP guidelines.

Methodology


The analytical procedure involves:
  • Preparing a test solution by dissolving 25 mg of Trimethoprim in mobile phase and diluting to 25 mL.
  • Preparing reference solution (a) by diluting 1 mL of test solution to 200 mL with mobile phase.
  • Preparing reference solution (b) by dissolving 5 mg each of Trimethoprim and Impurity-B in mobile phase and diluting to 100 mL.
  • Performing isocratic reversed-phase chromatography at 25 °C using a cyanopropyl column and phosphate buffer/methanol mobile phase at pH 3.1.
  • Detecting analytes with UV at 280 nm over a 30-minute run time.

Used Instrumentation


The following instrumentation was employed:
  • Liquid Chromatograph: UltiMate 3000 LC
  • Column: Betasil-CN (4.6 × 250 mm, 5 µm)
  • Detector: UV set to 280 nm

Main Results and Discussion


System suitability tests confirmed method performance:
  • Resolution between Trimethoprim and Impurity B: criterion ≥ 2.0; obtained 5.9.
  • Relative retention time (RRT) of Impurity H vs. Trimethoprim: expected ≈ 1.8; obtained 1.8.

Impurity I was not available at the time of analysis, so only Impurity H was assessed. The observed RRT for Impurity H met EP specifications, demonstrating method selectivity and precision.

Benefits and Practical Applications


This validated EP method enables pharmaceutical quality control laboratories to:
  • Accurately quantify key impurities in Trimethoprim batches.
  • Ensure compliance with pharmacopeial standards.
  • Support stability studies by monitoring impurity profiles over time.

Future Trends and Potential Uses


Emerging directions include:
  • Adoption of UHPLC formats to reduce run times and solvent consumption.
  • Integration with mass spectrometric detection for enhanced impurity identification.
  • Application of automated data analysis and machine learning for trend monitoring.

Conclusion


The EP-8.0 method for Trimethoprim impurities H and I has been successfully applied, meeting all system suitability criteria. Although Impurity I was unavailable, the validated procedure reliably detects Impurity H with high resolution and consistent retention time, ensuring robust impurity monitoring.

References


European Pharmacopoeia 8.0. Monograph for Trimethoprim Impurities Assay.

Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.

Downloadable PDF for viewing
 

Similar PDF

Impurities test for Trimethoprim (EP-8.0 method) - For Impurities-E, D, G, B, J and F
Impurities test for Sulfadiazine (EP-8.0 method)
Impurities test for Sulfadiazine (EP-8.0 method)
|Thermo Fisher Scientific|Applications
Impurities test for Mefenamic Acid (EP- method)
Impurities test for Mefenamic Acid (EP- method)
|Thermo Fisher Scientific|Applications
Impurities test for Metronidazole (EP-8.0 method)
Impurities test for Metronidazole (EP-8.0 method)
|Thermo Fisher Scientific|Applications